A 4-year prospective study of de novo acute myeloid leukaemia in patients aged 56 years and over was undertaken in the Northem Region of England (population 3.09 million).
The study was conducted to assess the incidence and outcome of treatment in all elderly patients diagnosed between January 1,1988 and December 31,1991.
Two hundred cases de novo AML were confirmed, giving an incidence of 6.05/105 per annum (age specific population) (95% CI, 5.2-6.9).
Acute promyelocytic leukaemia was rare.
Erythroleukaemia, monocytic leukaemia and AML with trilineage myelodysplasia were more common than in younger patients.
Karyotypic abnormalities classically associated with response to therapy were present in only six of 91 patients where cytogenetic data was available.
Treatment was at the discretion of the physician in charge : if given, specific treatment was recorded and clinical outcome assessed.
Only 84 (42%) of patients received treatment with curative intent.
Forty-four of 84 achieved a complete remission, usually of brief duration.
A normal karyotype in leukaemic cells was associated with a survival advantage in this group (p<0.05).
Mots-clés Pascal : Leucémie myéloblastique, Incidence, Epidémiologie, Nord, Angleterre, Grande Bretagne, Royaume Uni, Europe, Traitement, Pronostic, Adulte, Homme, Age mûr, Vieillard, Aigu, Hémopathie maligne
Mots-clés Pascal anglais : Acute myelocytic leukemia, Incidence, Epidemiology, North, England, Great Britain, United Kingdom, Europe, Treatment, Prognosis, Adult, Human, Middle age, Elderly, Acute, Malignant hemopathy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0243069
Code Inist : 002B19B. Création : 09/06/1995.